Superworth

MeiraGTx price to free cash flow MGTX

Market value divided by free cash flow over the last twelve months, since 2019.

Today, Nov 2, 2026
85.5×
7-year median
40.7×
Against its 7-year history
69th
percentile: 0 is its lowest day, 100 its highest
7-year range
18.3× to 310×
Peer median
30.3×

MeiraGTx's price to free cash flow is 85.5× as of Nov 2, 2026.

That is above its 7-year median of 40.7×, higher than on 69% of days in the last 7 years.

Over that time it ranged from 18.3× in Oct 2019 to 310× in Jul 2026.

The median for 4 biotech stocks of a similar size is 30.3×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far85.5×84.5×310×
2025n/m a value too high to mean anything
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
202042.9×31.4×48.5×
201942.2×18.3×44.6×

Against its peers

Companies in Biotechnology nearest MeiraGTx's size, closest first, today.

CompanyPrice to free cash flow
MGTXMeiraGTx85.5×
VCELVericel33.6×
ADMAAdma Biologics21.3×
PLXProtalix BioTherapeutics26.9×
KRYSKrystal Biotech34.0×
Peer median30.3×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on MeiraGTx

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.